In 2019, the CIRT study investigated the potential protective effect of low-dose methotrexate in CHD patients without RA, but it failed to prove it; between possible explanations, it is notable that the mean CRP levels of this study population (1.6 mg/L) was lower than both the median CRP levels of RA patients, as reported by Ajeganova et al. (131), and the residual inflammatory risk in CHD as currently defined (2 mg/L). The gene discussed is CRP; the disease is coronary artery disorder.